Netflix Cuts About 1,000 Jobs While Keeping Its Full-Year Forecast

Rivian is trying to become more than an electric-vehicle manufacturer without abandoning the vehicle business that funds its ambitions. The strategy combines the R2 launch with autonomy, an in-vehicle assistant, custom silicon and licensing to other automakers.

The commercial foundation is R2. Rivian's second-quarter filing said external deliveries began June 9 and described R2 as a way to reach a broader market. Spending on AI and autonomy only becomes an advantage if higher vehicle volume improves factory utilization and cash generation.

Beyond vehicles, Rivian has a $5.8 billion technology joint venture with Volkswagen Group focused on electrical architecture and software. Chief executive RJ Scaringe has discussed licensing to more brands and potentially adding AI and autonomy. Rivian also owns 31% of Mind Robotics, which could supply factories and outside customers.

The opportunity is a higher-margin mix of software, services and licensing. The risk is that several capital-intensive bets mature at different speeds while autos still need scale. The October 29 report should be judged on R2 efficiency, cash use, software revenue and evidence that outside partners will pay for Rivian technology.

Eaton's valuation asks investors to pay now for growth that still must translate into stronger margins. The source comparison, dated October 12, put Eaton at 43.3 times trailing earnings, above Emerson at 35.2 times, Parker Hannifin at 33.1 times and Hubbell at 27.8 times.

The premium has an operating foundation. Eaton's trailing revenue grew 15.5%, fastest in the selected group. Official second-quarter results showed sales of $8.5 billion, up 21%, with 14% organic growth. Management said data-center sales rose about 65%, while backlog across the electrical businesses was 43% higher than a year earlier.

The trade-off is profitability. The peer table put Eaton's trailing operating margin at 17.7%, below Emerson, Parker and Hubbell. Eaton's official second-quarter segment margin was 23.1%, down 80 basis points year over year, although it beat guidance. Those measures differ, but both keep price-cost execution in focus. Management guided to adjusted 2026 EPS of $13.40 to $13.60. If margins recover while backlog converts, the premium can hold. If costs stay ahead of price, the multiple leaves less room for disappointment.

Nike and Jordan products accounted for 72.3% of the tracked U.S. sneaker resale market in September, according to data reported by Citi, an increase of 63 basis points from the prior month.

That is a useful demand signal, especially because Jordan led the gains. A healthy secondary market can indicate cultural relevance, product scarcity and consumer willingness to pay. It can also help Nike manage launches and wholesale allocation.

Resale share is not the same as Nike revenue. Transactions occur between buyers and sellers after the original sale, and high prices may reflect deliberately limited supply rather than broad demand. The dataset's marketplace coverage and methodology also matter, so one month's movement should not be treated as a complete view of the brand.

Nike's own fiscal first-quarter results were more mixed. Revenue fell 4% to $11.2 billion, Nike Direct revenue declined to $4.1 billion from $4.5 billion, and inventory rose 5% from May to $7.8 billion. Gross margin improved 60 basis points to 42.8%, helped by lower warehousing and logistics costs. Management said work on Nike Sportswear, Jordan Brand and Greater China would extend beyond fiscal 2027.

The contrast is the real story. Resale data suggests continued heat in selected products, while company results show a broader portfolio still in transition. Investors should look for whether stronger resale demand translates into full-price sell-through, lower promotions and healthier inventory.

Nike benefits if Jordan momentum expands beyond scarce releases. Until that appears in reported revenue and margins, the 72.3% share is supporting evidence, not a turnaround verdict.

Paychex's quarterly dividend rose 10% in May to $1.19 a share, extending a post-pandemic pattern of annual increases even as the stock weakened.

The payout is supported by a recurring business. Paychex serves about 840,000 customers and processes payroll for roughly one in 11 U.S. private-sector workers. Fiscal 2026 operating cash flow was about $2.56 billion, compared with roughly $1.6 billion of dividends, putting the cash payout near 63% of operating cash flow. Measured against earnings, the ratio is higher because the company paid $4.43 a share against $5.51 of GAAP earnings.

That coverage is adequate, but not loose. Paychex also carries debt from its Paycor acquisition, so capital allocation must balance the dividend, integration, technology investment and deleveraging.

A second earnings stream comes from interest on client funds held briefly before payroll distribution. The company reported $49.8 million from those balances in the latest quarter and guided to $200 million to $210 million for fiscal 2027. Higher rates support that income; rate cuts would work in the other direction.

The sharper risk is a small-business downturn. Fewer employees and business closures can reduce processing revenue and the balances that generate float income at the same time. That two-part exposure matters more than a single month's jobs number.

Paychex has paid a quarterly dividend since 1988, and the current payout is backed by real cash generation. Continued increases will depend on client retention, payroll growth, Paycor integration and the interest-rate environment, not the historical pattern alone.

Moderna rose about 6% on October 15, outpacing BioNTech, Pfizer and the iShares Biotechnology ETF. The important qualification is that Moderna issued no new company announcement that day.

A broader move into healthcare can explain part of the gain, while Moderna's earlier melanoma results may explain why the stock moved more than its peers. In August, Moderna and Merck reported that intismeran autogene, used with Keytruda, met the primary endpoint in a late-stage trial. That result gave investors a company-specific reason to favor Moderna during a sector rally.

Neither explanation can be proven from price action alone. Flows, short covering, options positioning and investor expectations can all contribute to a large daily move. The stronger evidence will come from the full late-stage presentation expected at the European Society for Medical Oncology congress later in October.

The distinction matters because Moderna is still rebuilding its commercial base after the pandemic. Respiratory vaccines generate current revenue, but oncology offers the larger potential change in long-term value. Personalized cancer vaccines also require manufacturing, logistics and regulatory execution beyond a positive clinical endpoint.

Investors should therefore treat the rally as a change in expectations, not a new result. A durable rerating would require detailed efficacy, safety and subgroup data, followed by evidence that Moderna can manufacture individualized doses at commercial scale.

The October 15 move and the next day's reversal show how much anticipation is embedded in the shares. The upcoming melanoma dataset, rather than a one-day sector rotation, will decide whether that anticipation is justified.